Urologic Oncologist and Scientist at Northwestern University K-index:3.7
Chicago
Joined July 2009
- Tweets2.4K
- Following4K
- Followers3.8K
- Likes15K
Joshua Meeks retweeted
BCG has been used as an immunotherapy for bladder cancer for over 50 years, yet its immunoregulatory mechanisms and causes of resistance remain unclear.
doi.org/10.1172/JCI200442
Here, Joshua James Meeks @JoshMeeks, Weiguo Cui @Cui_Lab & team @NUFeinbergMed analyzed the tumor microenvironment in patients with bladder cancer, identifying dynamic regulation of myeloid-T cell interactions as a critical for outcomes of BCG.
The figure shows the study design and patient cohort for immune profiling of the bladder cancer tumor microenvironment during BCG therapy.
#BladderCancer #BCGtherapy
Joshua Meeks retweeted
Divergent macrophage-regulated T cell states determine response to Bacillus Calmette-Guérin vaccine in high-risk bladder cancer: doi.org/10.1172/JCI200442
Joshua Meeks retweeted
Exciting opportunity! The AUA is seeking a highly-qualified member to fill the position of AUA’s next Editor of The Journal of Urology®.
🚨 Apply by June 29, 2026 for consideration!
Learn more here ➡️ bit.ly/4aQjJfH
#TheVoiceofUrology
Joshua Meeks retweeted
Thanks so much @MarkTysonMD & @JoshMeeks !! Very appreciative of both of your support and help with the GAIN trial A032303 @ALLIANCE_org @SWOG @eaonc @NRGonc @theNCI
I agree - this is a GREAT trial and my patients have been enthusiastic so far. Thank you @eugene_pietzak for your leadership on this trial
Joshua Meeks retweeted
Presented at #ASCO26:
In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full phase 3 PROTEUS trial results: nej.md/3RuNe00
Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer nej.md/4dLeiiW
@ASCO
ALT A survival analysis graph from a study published in the New England Journal of Medicine shows the percentage of patients over time in months since randomization. The graph compares "ADT plus apalutamide" to "ADT plus placebo." Data includes hazard ratios and confidence intervals. The American Society of Clinical Oncology Meeting is mentioned at the top.
Joshua Meeks retweeted
We ran a mock ODAC for sasanlimab and durvalumab in high risk NMIBC. Results showed one of the agents received more support than the other. This felt surprising and is timely in vote of the recent FDA decisions. #ASCO26 👉 open.spotify.com/episode/2jM…
GI-Coffee study. Coffee vs alvimopan for MIBC after cystectomy for bowel recovery. Great study. Worry about contamination of baseline coffee use across both arms.
Please open and enroll to GAIN. @eugene_pietzak gem-bcg. Bcg exposed. Great trial. We have open and enrolling @NM_Urology
TIP#2. So excited for ARCIS. @SWOG. First RCT of BCG unresponsive NMIBC. CRETO-gem vs gem-doce.
@MarkTysonMD @cgoncology
Joshua Meeks retweeted
Come join us for a deep dive into Clinical Trials in Progress - Hall B, The Square, Learning Lab ... at 9 am ET TODAY #AUA26
Heading to #AUA26? Don’t miss the Clinical Trials in Progress (CTiP) session.
@bbmdmsk and I will be moderating a deep dive as presenters share the raw science and trial designs for the next generation of bladder cancer care - including novel ADCs, gene therapy, and intravesical drug-delivery systems.
Your questions and input could help shape these studies before they reach the finish line.
See you at the Learning Lab in The Square!
#Urology #BladderCancer #MedicalInnovation @AmerUrological
Joshua Meeks retweeted
The FDA approves the signatera ctDNA assay for muscle invasive bladder cancer patients post surgery.
This is based on the results of Imvigor011 study (atezo vs placebo in ctDNA positives, surveillance for the ctDNA negatives).
It opens a new chapter for personalised therapy in urothelial cancer. Focusing on early treatment for those patients that need it and sparing those at lower risk potentially harmful treatment makes sense.
‘It is the first companion diagnostic approval in the field of blood-based MRD.’
natera.com/company/news/sign…
Joshua Meeks retweeted
Congratulations to the newly awarded 2026 National Residency Abstract Olympics winners! 🏆
@CleClinicUro @NM_Urology @WCMUrology
#AUA26
Small numbers but improved cystectomy free survival and lower rates in bcg+durva arms of Potomac. Seems less bcg unresponsive. This may be the piece that matters #bladdercancer. #AUA26
